Altesa BioSciences

Altesa BioSciences is dedicated to improving the lives of people with chronic lung diseases by preemptively targeting the viral cause of acute exacerbations, rather than managing downstream consequences. Its mission centers on developing safe, effective oral medicines, starting with vapendavir for rhinovirus infections in COPD, which has shown promise in reducing symptoms, viral load, and illness duration in clinical trials. With a seasoned leadership team and plans for a pivotal Phase 2b study in 2026, Altesa is positioning itself to address a critical unmet need in respiratory medicine. The company's strategy leverages the growing availability of point-of-care diagnostics to enable timely, targeted antiviral intervention.

Platform focused on developing broad-spectrum, orally administered antiviral agents that target respiratory viruses, specifically rhinovirus, to prevent acute exacerbations in patients with chronic lung diseases.

Total raised: $99.2M

Altesa faces indirect competition from anti-inflammatory biologics for COPD (e.g., GSK's Nucala) but has no direct competitors with an approved antiviral for rhinovirus. Its main differentiation is a first-in-class, oral therapy that targets the root cause of most exacerbations, offering a proactive rather than reactive treatment approach.